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Background Current heart failure guidelines recommend target eplerenone dose of 50 mg/day. We have examined the effect
of different eplerenone doses based on pre-specified renal function stratification in the Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
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Methods
and results
In EMPHASIS-HF, the target dose of eplerenone/placebo was stratified at randomization according to esti-
mated glomerular filtration rate (eGFR): 50 mg/day if eGFR ≥ 50 mL/min/1.73 m2 and ≤ 25 mg/day if eGFR
30–49 mL/min/1.73 m2. Patients remained within these dose ranges during the trial (as per stratification). The
primary outcome was a composite of heart failure hospitalization or cardiovascular mortality. Eplerenone was
superior to placebo within each respective eGFR stratum [eplerenone vs. placebo in the eGFR ≥ 50 mL/min/1.73 m2
stratum: hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.45–0.74; and eplerenone vs. placebo in the eGFR
30–49 mL/min/1.73 m2 stratum: HR 0.62, 95% CI 0.49–0.78; Pinteraction = 0.89]. Despite receiving lower eplerenone
doses, patients in the eGFR 30–49 mL/min/1.73 m2 stratum more often had hyperkalaemia, renal failure events, and
drug discontinuation.
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Conclusion In EMPHASIS-HF the eplerenone dose was stratified according to renal function and the treatment effect was not
influenced by renal function: 25 mg/day in patients with eGFR 30–49 mL/min/1.73 m2 was as effective as 50 mg/day
in patients with eGFR>=50 mL/min/1.73 m2. However, patients with impaired renal function experienced more
adverse events, despite reveiving lower eplerenone doses. Current guidelines do not recommend tailoring the dose
of eplereone according to renal function but the current data suggest they should.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Eplerenone • Heart failure • Treatment dose • Renal function • Stratification
Introduction
Current heart failure (HF) guidelines recommend uptitration
of angiotensin-converting enzyme inhibitor (ACEi), angiotensin
receptor blocker (ARB), and beta-blocker doses to evidence-based
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. targets based upon those used in pivotal clinical trials in HF
with reduced ejection fraction (HFrEF). In ordinary practice, these
doses are not attained in many patients despite the randomized
evidence showing the benefit of higher ACEi/ARB and beta-blocker
doses.1–6
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By contrast, there is no study comparing different doses of min-
eralocorticoid receptor antagonists.7 For eplerenone, the current
guidelines recommend a starting dose of 25 mg/day and a target
dose of 50 mg/day regardless of renal function.1,2
In the Eplerenone in Mild Patients Hospitalization and Survival
Study in Heart Failure (EMPHASIS-HF), eplerenone reduced the
risk of death and the risk of hospitalization, compared to placebo,
in patients with HFrEF who were in New York Heart Association
(NYHA) functional class II at the time of randomization.8 Because
of pharmacokinetic and safety considerations, patients were strati-
fied at randomization to either a higher target dose (50 mg/day) of
placebo/eplerenone or to a lower target dose (up to 25 mg/day),
according to estimated glomerular filtration rate (eGFR) strata.
We used this pre-specified dose stratification to compare the
efficacy and safety of low-dose eplerenone vs. low-dose placebo




The design of EMPHASIS-HF has been published.8 In short,
EMPHASIS-HF was a randomized, double-blind trial in which 2737
patients in NYHA functional class II and with left ventricular ejec-
tion fraction ≤ 35% were randomized to eplerenone or placebo,
added to other recommended therapies. The primary outcome
was a composite of death from cardiovascular causes or hospi-
talization for HF (HFH). The median duration of follow-up was
21 months. The primary outcome occurred in 18.3% of patients in
the eplerenone group, compared with 25.9% in the placebo group




Patients were stratified to receive ‘high-dose’ or ‘low-dose’ study
treatment according to eGFR as per stratification protocol. The main
reason why a lower target dose of eplerenone was chosen in patients
with an eGFR between 30 and 49 mL/min/1.73 m2 was because in
the Eplerenone Post-Acute Myocardial Infarction Heart Failure Effi-
cacy and Survival Study (EPHESUS),9 where no pre-specified dose
allocation was performed, patients with eGFR < 50 mL/min/1.73 m2
had higher incidence of serious hyperkalaemia with eplerenone com-
pared to placebo (10.1% vs. 5.9%; P= 0.006), whereas in patients
with an eGFR ≥ 50 mL/min/1.73 m2 the corresponding hyperkalaemia
rates were much lower (4.6% vs. 3.5%; P= 0.04). In order to
avoid excessive side effects in high-risk patients with impaired
renal function, these received lower study drug doses by protocol
pre-specification.
In concordance, placebo/eplerenone was started at a dose of
≤ 25 mg/day and could be increased after 4 weeks up to 50 mg/day if the
eGFR was ≥ 50 mL/min/1.73 m2; or started at 25 mg on alternate days
and increased to 25 mg/day if the eGFR was 30–49 mL/min/1.73 m2.
By protocol, eplerenone/placebo doses were maintained in these dose
ranges with drug dose adjustments allowed according to potassium



















































































.. study drug dose would be decreased, and if the serum potassium level
was ≥ 6.0 mmol/L the study drug would be temporarily stopped. Potas-
sium was to be re-measured within 72 h after dose reduction or study
drug withdrawal, and the study drug was to be restarted only if the
level was < 5.0 mmol/L.
Statistical analysis
In descriptive analyses, continuous variables are expressed
as mean± standard deviation. Categorical variables are expressed
as frequencies and proportions (%). Comparison of patients in the
low-dose and high-dose strata and within each dose strata (placebo
vs. eplerenone) was performed using an independent samples t-test
and a chi-square test for categorical variables. Normality assumptions
were verified.
The primary outcome was a composite of HFH or cardiovascu-
lar mortality. Cox proportional hazard regression models were used
to model long-term event rates both in univariable and multivariable
analysis. Cox proportional hazards assumptions were assessed and no
violations were found. The variables used to adjust outcomes were
those used in a published risk model developed in EMPHASIS-HF,10
i.e. age, sex, systolic blood pressure, eGFR,11 diabetes, prior HFH,
haemoglobin, prior myocardial infarction/coronary artery bypass graft-
ing, and body mass index.
All analyses were performed with SAS® software version 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
Characteristics of the study population
Within the respective eGFR stratum, the randomization resulted
in treatment groups that were well balanced in terms of their
clinical characteristics, in accordance with the study overall
(Table 1).
Comparison of eplerenone and placebo
doses during the trial by estimated
glomerular filtration rate strata
The mean eplerenone/placebo doses in the eGFR
≥ 50 mL/min/1.73 m2 stratum were of 25 mg/day at the study
start, increased to ≥ 40 mg/day at week 4, and were main-
tained stable at ≥ 40 mg/day during the trial (Table 2). The mean
eplerenone/placebo doses in the eGFR 30–49 mL/min/1.73 m2
stratum were <17 mg/day at the study start, increased up to
23 mg/day at week 4, and did not exceed 30 mg/day during the trial
(Table 2 & Figure 2).
Comparison of eplerenone with placebo
by estimated glomerular filtration rate
strata
The event rate reduction with eplerenone compared to placebo
was similar within each eGFR stratum [eplerenone vs. placebo
in the eGFR ≥ 50 mL/min/1.73 m2 stratum: HR 0.58, 95%
CI 0.45–0.74; and eplerenone vs. placebo in the eGFR
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Table 1 Comparison of patients within each estimated glomerular filtration rate stratum at week 4
Patient characteristics eGFR stratum
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
≥ 50 mL/min/1.73 m2 P-value 30–49 mL/min/1.73 m2 P-value









. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 67.7 ± 7.3 67.7 ± 7.4 NS 69.8 ± 7.9 70.1 ± 7.0 NS
Male gender, n (%) 579 (78) 660 (80) NS 474 (77) 409 (75) NS
BMI (kg/m2) 27.6 ± 4.9 27.6 ± 4.7 NS 27.4 ± 5.0 27.4 ± 5.0 NS
SBP (mmHg) 125 ± 17 125 ± 16 NS 123 ± 18 122 ± 17 NS
Heart rate (b.p.m.) 74 ± 16 73 ± 15 NS 73 ± 15 74 ± 16 NS
Laboratory
eGFR (mL/min/1.73 m2) 78 ± 20 76 ± 20 0.048 63 ± 20 62 ± 22 NS
Haemoglobin (g/dL) 13.9 ± 1.5 13.9 ± 1.6 NS 13.7 ± 1.6 13.6 ± 1.6 NS
Sodium (mmol/L) 140 ± 4 140 ± 4 NS 140 ± 4 139 ± 4 NS
Potassium (mmo/L) 4.2 ± 0.4 4.3 ± 0.4 <0.001 4.3 ± 0.5 4.3 ± 0.4 NS
Echocardiography
LVEF (%) 26 ± 5 26 ± 5 NS 26 ± 5 26 ± 5 NS
Co-morbidities, n (%)
Diabetes 235 (32) 225 (27) NS 222 (36) 173 (32) NS
AF 221 (30) 243 (30) NS 188 (30) 189 (35) NS
Prior HFH 365 (49) 409 (50) NS 346 (56) 313 (58) NS
Prior MI 378 (51) 414 (50) NS 352 (57) 279 (51) NS
ICD/CRT 133 (18) 160 (19) NS 166 (27) 150 (28) NS
Medications, n (%)
ACEi/ARB 708 (95) 784 (95) NS 589 (95) 507 (93) NS
Beta-blocker 661 (89) 745 (90) NS 540 (87) 468 (86) NS
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; eGFR,
estimated glomerular filtration rate; HFH, hospitalization for heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; SBP, systolic blood pressure.
Table 2 Mean eplerenone/placebo doses (in mg) within each estimated glomerular filtration rate stratum during the
trial
eGFR stratum
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
≥ 50 mL/min/1.73 m2 30–49 mL/min/1.73 m2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
High-dose eplerenone High-dose placebo Low-dose eplerenone Low-dose placebo
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study start 24.7 ± 2.6 24.8 ± 2.7 17.0 ± 6.4 16.1 ± 5.6
Week 4 38.9 ± 13.2 40.4 ± 12.7 23.4 ± 9.6 23.3 ± 9.8
Month 5 42.0 ± 12.3 43.6 ± 11.2 24.8 ± 10.8 27.3 ± 11.6
Month 12 42.3 ± 12.4 43.9 ± 11.1 26.8 ± 12.3 30.2 ± 12.6
Month 24 41.6 ± 12.5 43.7 ± 11.3 28.0 ± 11.2 30.8 ± 12.7
Study end 39.8 ± 13.3 41.8 ± 12.3 24.6 ± 11.6 26.3 ± 12.7
eGFR, estimated glomerular filtration rate.
30–49 mL/min/1.73 m2 stratum: HR 0.62, 95% CI 0.49–0.78;
between strata Pinteraction = 0.89] (Table 3 and Figure 1).
Adverse events
Hyperkalaemia (K+ > 5.5 mmol/L) was more frequent with
eplerenone compared to placebo regardless of the eGFR stratum.











. were more frequent with low-dose eplerenone/placebo (i.e. eGFR
30–49 mL/min/1.73 m2 stratum) compared with high-dose (i.e.
eGFR ≥ 50 mL/min/1.73 m2 stratum). For example, hyperkalaemia
was observed in 1% and 4% of patients randomized to placebo
and eplerenone, respectively, in the eGFR ≥ 50 mL/min/1.73 m2
stratum, whereas these proportions increased to 7% with placebo
and 13% with eplerenone in the eGFR 30–49 mL/min/1.73 m2
stratum (P< 0.001) (Table 4).
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Figure 1 Kaplan–Meier curves for the primary outcome of hospitalization for heart failure or cardiovascular mortality of eplerenone vs.
placebo within estimated glomerular filtration rate (eGFR) strata. Between eGFR strata. Pinteraction = 0.89.
Figure 2 Eplerenone doses by renal function strata. eGFR, estimated glomerular filtration rate in mL/min/1.73 m2; Eple., eplerenone; Plc.,
placebo.
Discussion
In EMPHASIS-HF, the efficacy of eplerenone was not influ-
enced by eGFR, i.e. the treatment effect was similar regardless
of the eGFR stratum. However, as per stratification, eplerenone/
placebo doses were much lower in patients with eGFR










. effects were observed more often. Therefore, using high (up
to 50 mg/day) eplerenone doses in patients with impaired renal
function may greatly increase the rates of adverse events and drug
discontinuation. Current HFrEF treatment guidelines do not spec-
ify that the initial dose of eplerenone should be adjusted according
to renal function. However, we believe that these data show that
they should, in keeping with the EMPHASIS-HF protocol.
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.. To date, no randomized trials exist directly comparing different
doses of eplerenone (or any other aldosterone antagonist). There
are, however, two large trials in which patients were prospectively
randomized to a high or low dose of ACEi or ARB: the Assess-
ment of Treatment with Lisinopril and Survival (ATLAS) trial12
and the Heart failure Endpoint evaluation with the Angiotensin II
Antagonist Losartan (HEAAL) trial.13 In ATLAS, 3164 HF patients
with an ejection fraction ≤ 30% were randomized to double-blind
treatment with either low doses (2.5–5.0 mg/day, n=1596) or
high doses (32.5–35 mg/day, n=1568) of the ACEi lisinopril. Com-
pared with the low-dose group, patients in the high-dose group
had a significant 12% lower relative risk of death or hospitalization
for any reason (P= 0.002) and 24% fewer HFH (P= 0.002). Drug
discontinuation due to side effects was similar between groups.12
In HEAAL, 3846 HF patients with an ejection fraction ≤ 40%
and intolerance to ACEi were randomly assigned to low dose
(50 mg/day, n=1919) or high dose (150 mg/day, n=1927) of the
ARB losartan. Compared with the low-dose group, patients in the
high-dose group had a significant 10% lower relative risk of death
or HFH (P= 0.027) and 13% fewer HFH (P= 0.025). Drug discon-
tinuation due to side effects was also similar between groups.13
These findings indicate that HF patients should not be maintained
on low doses of an ACEi or ARB (unless these are the only doses
that can be tolerated). In contrast, mineralocorticoid receptor
antagonist dose comparisons have not been performed to date.
The design of EMPHASIS-HF was different: by stratification, two
dose levels were compared with placebo rather than directly low
vs. high treatment dose. It should be pointed out that, unlike
ATLAS and HEAAL, EMPHASIS-HF patients were randomized
within two strata which were determined by renal function,
hence high-dose vs. low-dose treatment cannot be compared. In
EMPHASIS-HF, low-dose was as effective as high-dose eplerenone
when used in appropriate patients (i.e. low dose for patients with
eGFR 30–49 mL/min/1.73 m2 and high dose for patients with eGFR
≥ 50 mL/min/1.73 m2), supporting the use of eplerenone at doses
around 25 mg/day in patients with eGFR 30–49 mL/min/1.73 m2
and around 50 mg/day in patients with eGFR ≥ 50 mL/min/1.73 m2,
adapting for potassium levels if required.
Stratification is usually performed to ensure that powerful
predictors of outcome or response to treatment are balanced
between randomization groups, but stratification is also the
only situation in which balanced randomization is maintained
in subgroups, since the randomization is performed within
each stratum.14 Therefore, stratified analyses are less suscep-
tible to bias caused by imbalances in treatment allocation and
patient characteristics, which inevitably hamper all analyses
made on subgroups based on non-randomized baseline charac-
teristics. In the absence of a statistical interaction (i.e. similar
between-strata HRs, as observed herein), the treatment effect
can be considered similar between both strata provided that
the same strata treatment doses are used in clinical practice.
These findings should thus change current guidelines where no
eGFR-specific eplerenone dose recommendation is provided,1,2
and many patients may be receiving inappropriate doses of
eplerenone contributing to higher rates of hyperkalaemia and drug
discontinuation.15
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Table 4 Investigator-reported adverse events by allocation dose






. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
≥ 50 mL/min/1.73 m2 P-value 30–49 mL/min/1.73 m2 P-value









. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hyperkalaemia 27 (3.6%) 11 (1.3%) 0.005 82 (13.3%) 39 (7.2%) < 0.001 < 0.001 < 0.001
Hypokalaemia 5 (0.7%) 18 (2.2%) 0.018 11 (1.8%) 12 (2.2%) 0.68 0.064 1
Renal failure 9 (1.2%) 14 (1.7%) 0.53 29 (4.7%) 27 (5.0%) 0.89 < 0.001 0.001
Drug discontinuation 74 (10.0%) 108 (13.1%) 0.058 114 (18.4%) 114 (21.0%) 0.30 < 0.001 < 0.001
eGFR, estimated glomerular filtration rate.
In summary, the present analysis of stratified randomized data
from EMPHASIS-HF provides robust evidence that eplerenone
is equally beneficial and should be used in clinical practice at
the respective target doses of 50 mg/day in patients with eGFR
≥ 50 mL/min/1.73 m2 and 25 mg/day in patients with eGFR between
30 and 49 mL/min/1.73 m2.
Limitations
This is an analysis of pre-specified strata. Hence, our findings are
as robust as the main randomized clinical trial because no statis-
tical interaction (i.e. treatment effect differences) was observed
between strata.
Conclusion
In EMPHASIS-HF the eplerenone dose was stratified according
to renal function and the treatment effect was not influ-
enced by renal function: 25 mg/day in patients with eGFR
30–49 mL/min/1.73 m2 were as effective as 50 mg/day in
patients with eGFR>=50 mL/min/1.73 m2. However, patients
with impaired renal function experienced more adverse events
despite reveiving lower eplerenone doses. Current guidelines do
not recommend tailoring the dose of eplereone according to renal
function but the current data suggest they should.
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